Kraig Biocraft Laboratories, Inc., a U.S.-based company operating primarily in Lansing, has been making strides in the materials sector with a focus on the chemicals industry. The company leverages advanced recombinant DNA technology to develop high-strength, protein-based fibers aimed at commercial applications within the textile and specialty fiber industries. Their mission is to transform the traditional materials industry by offering innovative, sustainable, and high-performance materials derived from nature’s building blocks.
As of March 6, 2026, Kraig Biocraft Laboratories (KRAG) has not reported any new headlines. The most recent article, dated March 5, 2026, highlighted a significant milestone for the company’s “Project Atlas,” which focuses on industrial and defense biomaterials. This project underscores the company’s commitment to advancing biomaterials technology for critical applications.
In terms of market performance, the company’s stock has experienced fluctuations over the past year. The last closing price was recorded at $0.12. Over the past 52 weeks, the stock reached a high of $0.15 on March 1, 2026, and a low of $0.07 on February 5, 2026. These figures reflect the volatility and challenges faced by the company in the market.
Financially, Kraig Biocraft Laboratories is currently positioned with a negative earnings base, as indicated by a price-to-earnings ratio of -32.8. Additionally, the price-to-book ratio stands at -11.6245, highlighting the company’s ongoing financial challenges. Despite these metrics, the company maintains a market capitalization of approximately $125.29 million.
Kraig Biocraft Laboratories is traded on the OTC Bulletin Board, and further information about their work and achievements can be found on their website at www.kraiglabs.com . The company continues to focus on its mission to revolutionize the materials industry through sustainable and innovative solutions.
